Atul Deodhar

16.6k total citations · 3 hit papers
307 papers, 9.1k citations indexed

About

Atul Deodhar is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Atul Deodhar has authored 307 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 270 papers in Rheumatology, 179 papers in Immunology and 78 papers in Hematology. Recurrent topics in Atul Deodhar's work include Spondyloarthritis Studies and Treatments (241 papers), Rheumatoid Arthritis Research and Therapies (192 papers) and Psoriasis: Treatment and Pathogenesis (167 papers). Atul Deodhar is often cited by papers focused on Spondyloarthritis Studies and Treatments (241 papers), Rheumatoid Arthritis Research and Therapies (192 papers) and Psoriasis: Treatment and Pathogenesis (167 papers). Atul Deodhar collaborates with scholars based in United States, Germany and United Kingdom. Atul Deodhar's co-authors include Désirée van der Heijde, Xenofon Baraliakos, Jürgen Braun, Joachim Sieper, Philip J. Mease, Brian Porter, Maxime Dougados, Anthony D. Woolf, S. P. Raychaudhuri and Bengt Hoepken and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Atul Deodhar

294 papers receiving 8.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

2015 732 citations Dominique Baeten, Joachim Sieper et al. profile →
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

2020 233 citations Atul Deodhar, Philip Helliwell et al. profile →
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

2023 124 citations Gerd R Burmester, Stanley Cohen et al. RMD Open profile →

Peers

Countries citing papers authored by Atul Deodhar

Since Specialization

Citations

This map shows the geographic impact of Atul Deodhar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atul Deodhar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atul Deodhar more than expected).

Fields of papers citing papers by Atul Deodhar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Atul Deodhar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atul Deodhar. The network helps show where Atul Deodhar may publish in the future.

Co-authorship network of co-authors of Atul Deodhar

This figure shows the co-authorship network connecting the top 25 collaborators of Atul Deodhar. A scholar is included among the top collaborators of Atul Deodhar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Atul Deodhar. Atul Deodhar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events 2025 ·Dermatology and Therapy ·Mark Lebwohl, Atul Deodhar, Sergio Schwartzman, Carlo Salvarani, (unknown), Natalia Bello, (unknown), (unknown), (unknown), Marcus Ngantcha, Proton Rahman, Kim Papp, Joseph F. Merola, Alice B. Gottlieb, Andrew Blauvelt	2
2	Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies 2025 ·Lara D. Veeken ·Xenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, Filip Van den Bosch, Marina Magrey, Walter P. Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, (unknown), (unknown), (unknown), (unknown), Lianne S. Gensler	1
3	P171 Bimekizumab impact on core group for research and assessment of psoriasis and psoriatic arthritis domains for patients with psoriatic arthritis: 52-week results from four phase 3 studies 2024 ·Lara D. Veeken ·Joseph F. Merola, Philip J. Mease, Atul Deodhar, Barbara Ink, C. Fleurinck, Rajan Bajracharya, Jason Coarse, Laura C. Coates	1
4	AB1104 STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY 2023 ·Christopher T. Ritchlin, Philip J. Mease, Wolf‐Henning Boehncke, John Tesser, (unknown), (unknown), M. Shawi, Elena Schiopu, Joseph F. Merola, Iain B. McInnes, Atul Deodhar	2
5	Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis breakdown → 2023 ·RMD Open ·Gerd R Burmester, Stanley Cohen, Kevin Winthrop, Peter Nash, Alan D. Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P. Lacerda, Hannah Palac, Tim Shaw, Philip J. Mease, Emma Guttman‐Yassky	124
6	Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis 2023 ·Drug Safety ·Bruce Strober, Laura C. Coates, Mark Lebwohl, Atul Deodhar, (unknown), (unknown), Alexa P. Kollmeier, Megan Miller, Yanli Wang, Shu Li, Soumya D. Chakravarty, Daphne Chan, M. Shawi, Ya‐Wen Yang, (unknown), Proton Rahman	31
7	Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study 2023 ·Rheumatology and Therapy ·Philip J. Mease, Dafna D. Gladman, Denis Poddubnyy, Soumya D. Chakravarty, M. Shawi, Alexa P. Kollmeier, Xie L. Xu, Stephen Xu, Atul Deodhar, Xenofon Baraliakos	11
8	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies 2022 ·RMD Open ·Christopher T. Ritchlin, Philip J. Mease, Wolf‐Henning Boehncke, John Tesser, Elena Schiopu, Soumya D. Chakravarty, Alexa P. Kollmeier, Xie L. Xu, M. Shawi, (unknown), Shihong Sheng, Yanli Wang, Stephen Xu, Joseph F. Merola, Iain B. McInnes, Atul Deodhar	18
9	Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging 2022 ·Lara D. Veeken ·Walter P. Maksymowych, Rebecca Bolce, Gaia Gallo, (unknown), (unknown), David Sandoval, Mikkel Østergaard, Kurisu Tada, Xenofon Baraliakos, Atul Deodhar, Lianne S. Gensler	10
10	Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial 2022 ·RMD Open ·Philip Helliwell, Phillip J. Mease, Arthur Kavanaugh, Laura C. Coates, Alexis Ogdie, Atul Deodhar, Vibeke Strand, Gregory Kricorian, (unknown), David H. Collier, Dafna D. Gladman	4
11	Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial 2022 ·Trials ·Dafna D. Gladman, Philip J. Mease, Paul Bird, Enrique R. Soriano, Soumya D. Chakravarty, M. Shawi, Stephen Xu, (unknown), (unknown), (unknown), Denis Poddubnyy, Lai‐Shan Tam, Philip Helliwell, Arthur Kavanaugh, Atul Deodhar, Mikkel Østergaard, Xenofon Baraliakos	34
12	Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis 2022 ·JCR Journal of Clinical Rheumatology ·Atul Deodhar, Soumya D. Chakravarty, Natalie J. Shiff, Kim Hung Lo, Stephen Xu, Elizabeth C. Hsia, Abhijeet Danve, John D. Reveille	1
13	Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) 2019 ·Annals of the Rheumatic Diseases ·Maxime Dougados, James Cheng‐Chung Wei, Robert Landewé, Joachim Sieper, Xenofon Baraliakos, Filip Van den Bosch, Walter P. Maksymowych, Joerg Ermann, Jessica A. Walsh, Tetsuya Tomita, Atul Deodhar, Désirée van der Heijde, Xiaoqi Li, Fangyi Zhao, Clinton C. Bertram, Gaia Gallo, Hilde Carlier, Lianne S. Gensler	86
14	Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis 2019 ·Queensland's institutional digital repository (The University of Queensland) ·Iain B. McInnes, Dafna D. Gladman, Atul Deodhar, Corinne Miceli‐Richard, Peter Nash, Naveed Sattar, Nehal N. Mehta, Darren L. Asquith, (unknown), Hanno B. Richards, Luminita Pricop, Abhijit Shete	1
15	Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies 2018 ·RMD Open ·Jürgen Braun, Atul Deodhar, Robert Landewé, Xenofon Baraliakos, Corinne Miceli‐Richard, Joachim Sieper, Erhard Quebe‐Fehling, Ruvie Martin, Brian Porter, Kunal K. Gandhi, Désirée van der Heijde, (unknown)	24
16	Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study 2017 ·Rheumatology and Therapy ·Hasan Tahir, Atul Deodhar, Mark C. Genovese, Tsutomu Takeuchi, Jacob Aelion, Filip Van den Bosch, Sibylle Haemmerle, Hanno B. Richards	27
17	Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. 2017 ·PubMed ·Xenofon Baraliakos, Alan Kivitz, Atul Deodhar, Jürgen Braun, James Cheng‐Chung Wei, Eumorphia Maria Delicha, Zsolt Talloczy, Brian Porter	69
18	CERTOLIZUMAB PEGOL FOR THE TREATMENT OF PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA TRIAL 2016 ·Clinical and Experimental Rheumatology ·Philip J. Mease, Roy Fleischmann, J. Wollenhaupt, Atul Deodhar, Dafna D. Gladman, Bengt Hoepken, Luke Peterson, D. van der Heijde	2
19	IL-17 Inhibition: Emerging Perspectives in the Future Management of Axial Spondyloarthritis 2015 ·SHILAP Revista de lepidopterología ·Atul Deodhar, Dirk Elewaut, Dominique Baeten, Xenofon Baraliakos	0
20	The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis 2013 ·Lara D. Veeken ·Daniel E. Fürst, Jonathan Kay, Mary Chester Wasko, Edward Keystone, Arthur Kavanaugh, Atul Deodhar, Frederick T. Murphy, Jeanette H. Magnus, Elizabeth C. Hsia, Benjamin Hsu, Stephen Xu, Mahboob U. Rahman, Mittie K. Doyle	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact